Loading...
Market
What will be the performance of Zevra Therapeutics' stock price by end of 2024?
2
Resolution / Starting Odds
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Stock market data from NASDAQ or NYSE
Story
Zevra's Miplyffa Receives FDA Approval, Eligible for $150M Voucher
Sep 20, 2024, 03:00 PM
Zevra Therapeutics, formerly KemPharm, has received FDA approval for its drug Miplyffa (arimoclomol) to treat Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. This approval makes Miplyffa the first treatment to be approved for NPC. The approval also makes Zevra eligible to receive a Priority Review Voucher worth approximately $150 million. Miplyffa is approved for use in combination with miglustat for patients aged 2 and older. The PDUFA date for the drug was September 21, 2024.
View original story
Similar markets
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Increase by more than 20% • 25%
Decrease by more than 20% • 25%
Remain within ±20% • 25%
Other • 25%
Yes • 50%
No • 50%
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Decrease by 5% or more • 25%
Change between -5% and 5% • 25%
Increase between 5% and 10% • 25%
Increase by 10% or more • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
Decrease • 25%